Abstract
Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Current Medicinal Chemistry
Title: Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects
Volume: 15 Issue: 10
Author(s): Naohiro Seo, Hiromichi Yamashiro and Toshimasa Tadaki
Affiliation:
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Abstract: Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Export Options
About this article
Cite this article as:
Seo Naohiro, Yamashiro Hiromichi and Tadaki Toshimasa, Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects, Current Medicinal Chemistry 2008; 15 (10) . https://dx.doi.org/10.2174/092986708784049603
DOI https://dx.doi.org/10.2174/092986708784049603 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Self-Nonself” Peptides in the Design of Vaccines
Current Pharmaceutical Design Assessment of Signal Peptides to Optimize Interleukin 2 (IL-2) Folding and Expression
Current Proteomics Evidence for a Putative Relationship Between Type 2 Diabetes and Neoplasia with Particular Reference to Breast Cancer: Role of Hormones, Growth Factors and Specific Receptors
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines
Current Topics in Medicinal Chemistry Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Remote Ischemic Conditioning Improves Cognitive Function During Cerebral Vascular Injury Through the Induction of Autophagy
Current Neurovascular Research Radiopharmaceutical Chemistry with Iodine-124: A Non-Standard Radiohalogen for Positron Emission Tomography
Medicinal Chemistry Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Ceramic Nanoparticles: Fabrication Methods and Applications in Drug Delivery
Current Pharmaceutical Design Use of Genetically Modified Bacteria to Modulate Adaptive Immunity
Current Gene Therapy <i>In Silico</i> and <i>in Vitro</i> Evaluation of Deamidation Effects on the Stability of the Fusion Toxin DAB<sub>389</sub>IL-2
Current Proteomics Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Progress and Prospects: The Use of 3D Spheroid Model as a Relevant Way to Study and Optimize DNA Electrotransfer
Current Gene Therapy Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry IgG4-Related Disease (IgG4+MOLPS) – Diagnostic Criteria and Diagnostic Problems
Current Immunology Reviews (Discontinued) Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Deubiquitinating Enzymes: Their Functions and Substrate Specificity
Current Protein & Peptide Science CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets